Cargando…
Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies
Diffuse intrinsic pontine glioma (DIPG) is the most lethal tumor involving the pediatric central nervous system. The median survival of children that are diagnosed with DIPG is only 9 to 11 months. More than 200 clinical trials have failed to increase the survival outcomes using conventional cytotox...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9502387/ https://www.ncbi.nlm.nih.gov/pubmed/36145510 http://dx.doi.org/10.3390/pharmaceutics14091762 |
_version_ | 1784795692555829248 |
---|---|
author | Liu, Guohao Qiu, Yanmei Zhang, Po Chen, Zirong Chen, Sui Huang, Weida Wang, Baofeng Yu, Xingjiang Guo, Dongsheng |
author_facet | Liu, Guohao Qiu, Yanmei Zhang, Po Chen, Zirong Chen, Sui Huang, Weida Wang, Baofeng Yu, Xingjiang Guo, Dongsheng |
author_sort | Liu, Guohao |
collection | PubMed |
description | Diffuse intrinsic pontine glioma (DIPG) is the most lethal tumor involving the pediatric central nervous system. The median survival of children that are diagnosed with DIPG is only 9 to 11 months. More than 200 clinical trials have failed to increase the survival outcomes using conventional cytotoxic or myeloablative chemotherapy. Immunotherapy presents exciting therapeutic opportunities against DIPG that is characterized by unique and heterogeneous features. However, the non-inflammatory DIPG microenvironment greatly limits the role of immunotherapy in DIPG. Encouragingly, the induction of immunogenic cell death, accompanied by the release of damage-associated molecular patterns (DAMPs) shows satisfactory efficacy of immune stimulation and antitumor strategies. This review dwells on the dilemma and advances in immunotherapy for DIPG, and the potential efficacy of immunogenic cell death (ICD) in the immunotherapy of DIPG. |
format | Online Article Text |
id | pubmed-9502387 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95023872022-09-24 Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies Liu, Guohao Qiu, Yanmei Zhang, Po Chen, Zirong Chen, Sui Huang, Weida Wang, Baofeng Yu, Xingjiang Guo, Dongsheng Pharmaceutics Review Diffuse intrinsic pontine glioma (DIPG) is the most lethal tumor involving the pediatric central nervous system. The median survival of children that are diagnosed with DIPG is only 9 to 11 months. More than 200 clinical trials have failed to increase the survival outcomes using conventional cytotoxic or myeloablative chemotherapy. Immunotherapy presents exciting therapeutic opportunities against DIPG that is characterized by unique and heterogeneous features. However, the non-inflammatory DIPG microenvironment greatly limits the role of immunotherapy in DIPG. Encouragingly, the induction of immunogenic cell death, accompanied by the release of damage-associated molecular patterns (DAMPs) shows satisfactory efficacy of immune stimulation and antitumor strategies. This review dwells on the dilemma and advances in immunotherapy for DIPG, and the potential efficacy of immunogenic cell death (ICD) in the immunotherapy of DIPG. MDPI 2022-08-24 /pmc/articles/PMC9502387/ /pubmed/36145510 http://dx.doi.org/10.3390/pharmaceutics14091762 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Liu, Guohao Qiu, Yanmei Zhang, Po Chen, Zirong Chen, Sui Huang, Weida Wang, Baofeng Yu, Xingjiang Guo, Dongsheng Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies |
title | Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies |
title_full | Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies |
title_fullStr | Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies |
title_full_unstemmed | Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies |
title_short | Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies |
title_sort | immunogenic cell death enhances immunotherapy of diffuse intrinsic pontine glioma: from preclinical to clinical studies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9502387/ https://www.ncbi.nlm.nih.gov/pubmed/36145510 http://dx.doi.org/10.3390/pharmaceutics14091762 |
work_keys_str_mv | AT liuguohao immunogeniccelldeathenhancesimmunotherapyofdiffuseintrinsicpontinegliomafrompreclinicaltoclinicalstudies AT qiuyanmei immunogeniccelldeathenhancesimmunotherapyofdiffuseintrinsicpontinegliomafrompreclinicaltoclinicalstudies AT zhangpo immunogeniccelldeathenhancesimmunotherapyofdiffuseintrinsicpontinegliomafrompreclinicaltoclinicalstudies AT chenzirong immunogeniccelldeathenhancesimmunotherapyofdiffuseintrinsicpontinegliomafrompreclinicaltoclinicalstudies AT chensui immunogeniccelldeathenhancesimmunotherapyofdiffuseintrinsicpontinegliomafrompreclinicaltoclinicalstudies AT huangweida immunogeniccelldeathenhancesimmunotherapyofdiffuseintrinsicpontinegliomafrompreclinicaltoclinicalstudies AT wangbaofeng immunogeniccelldeathenhancesimmunotherapyofdiffuseintrinsicpontinegliomafrompreclinicaltoclinicalstudies AT yuxingjiang immunogeniccelldeathenhancesimmunotherapyofdiffuseintrinsicpontinegliomafrompreclinicaltoclinicalstudies AT guodongsheng immunogeniccelldeathenhancesimmunotherapyofdiffuseintrinsicpontinegliomafrompreclinicaltoclinicalstudies |